Drug Profile
GSK 1070806
Alternative Names: GSK-1070806Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 18 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- No development reported Crohn's disease; Delayed graft function; Inflammatory bowel diseases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 15 Nov 2023 Phase-II clinical trials in Atopic dermatitis (In adults, In the elderly, Treatment-experienced) in USA, Canada (SC) (NCT05999799) (EudraCT2023-505414-15-00)
- 08 Nov 2023 Phase-II clinical trials in Atopic dermatitis (unspecified route), prior to November 2023 (GSK pipeline, November 2023)
- 24 Aug 2023 GlaxoSmithKline plans a phase II trials for Atopic Dermatitis (In adults, In the elderly, Treatment-experienced) (SC, Injection), in December 2023 (NCT05999799) (EudraCT2023-505414-15-00)